MAPT and depressive symptom measurement: Prior studies have shown that, among amyloid-positive individuals, depressive symptoms predict faster tau progression (Talmasov et al., 2025), whereas in LLD the severity of depressive symptoms and cognitive change is not directly linked to Aβ load (Kim et al., 2024), indicating that tau should be considered when examining depression–AD links (Byeon et al., 2025).